Pharma’s Adherence Allies: Part D Hearing Underscores Industry Progress in Reframing Rebate Debate

Sen. Bill Nelson is the primary sponsor of legislation to impose rebates on Medicare Part D. But when he held a hearing on the program in his Aging Committee, something surprising happened: everyone wanted to talk about adherence instead.

Congressional witnesses are carefully coached on how to answer hostile questions. One trick is to start by thanking the Congressman or Senator for the question: it keeps a civil, cordial tone—and buys a bit of time to think of how to frame a response that focuses on the witness’ agenda, rather than the questioner’s.

But when Pharmaceutical Research & Manufacturers of America SVP Richard Smith thanked Sen. Elizabeth Warren (D-Mass.) for her first question...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medicare

Medicaid Changes Could Have Major Impact on Recent Coverage Improvements

 
• By 

Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By 

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

How Could MFN Pricing Impact Commercial Market?

 
• By 

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

More from Government Payers